AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01454895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Web-based information
Description: This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
Study NCT01454895 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interactive Web-based information
Description: This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
Study NCT01163929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks
Study NCT04738370 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: Bloods +/- urine +/- vaginal swabs taken
Study NCT01527058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs
Study NCT04600518 — intervention group
Intervention type: DEVICE
Intervention: nProfiler I Stomach Cancer Assay Kit
Description: nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Study NCT03803956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT
Description: The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
Study NCT03803956 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT
Description: The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
Study NCT02360358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiscover
Description: two step procedure, week 0 and week1. Dosage depends on wound size.
Study NCT00555165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telescope prosthesis
Description: Monocular implantation of the telescope prosthesis after cataract extraction
Study NCT02360358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AS210
Description: two step procedure, week 0 and week1. Dosage depends on wound size.
Study NCT00764465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: 300 mg BID
Study NCT00764465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400 mg BID, 700 mg BID or 1400 mg QD
Study NCT01747954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bag Squeezing
Description: To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
Study NCT01747954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic vibrocompression
Description: To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
Study NCT03487471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Real-time elastography
Description: Breast ultrasound with real-time elastography
Study NCT03487471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Shear wave elastography
Description: Breast ultrasound with shear wave elastography
Study NCT02816606 — intervention group
Intervention type: PROCEDURE
Intervention: Flexible reamers
Description: These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
Study NCT02816606 — intervention group
Intervention type: PROCEDURE
Intervention: 70-degree arthroscope
Description: Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
Study NCT01564537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT01564537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules
Study NCT01564537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide capsules
Study NCT01564537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT01564537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT01564537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib placebo-matching capsules
Study NCT03856827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-6463
Description: IW-6463 Tablet
Study NCT03856827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo Tablet
Study NCT03082092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Sodium Succinate
Description: single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
Study NCT03082092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
Study NCT00245037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Study NCT00245037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines.
Study NCT00245037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d.
Study NCT00245037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~* Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~* Monitoring: Fludarabine level is not monitored.~* Dose Adjustments: There are no provisions for fludarabine dose adjustments.
Study NCT00245037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~* Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~* Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).
Study NCT00245037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~* In autologous transplants, patients receive their own stem cells.~* In syngeneic transplants, patients receive stem cells from their identical twin.~* In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used.
Study NCT00245037 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~* Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~* Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min.
Study NCT00245037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~* Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~* Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all).
Study NCT00245037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: This drug is used to prevent seizures while on chemotherapy.
Study NCT00245037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
Study NCT02524158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy for CLBP
Description: Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
Study NCT03536832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section with Vicryl
Description: Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
Study NCT03536832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section with Prolen
Description: Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
Study NCT01439594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH OFDI Imaging
Description: Imaging of Esophagus with OFDI system
Study NCT03100058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.
Study NCT03395197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib with enzalutamide
Description: Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
Study NCT03395197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo with enzalutamide
Description: Placebo plus enzalutamide 160 mg/day
Study NCT04555694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Used to increase tear production in patients who have dry eye caused by inflammation
Study NCT03100058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04035239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGS goggles
Description: BGS goggles use for 3-6 weeks
Study NCT00004883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00004883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00974922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
Study NCT00974922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 3000 I.U. once daily for 6 weeks
Study NCT00974922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for two weeks
Study NCT02738710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transumbilical incision
Description: incision within umbilicus
Study NCT02738710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra umbilical incision
Description: incision about 1 cm below umbilicus
Study NCT00929851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535
Description: Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
Study NCT00929851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate
Description: Formoterol fumarate 12 µg per metered dose
Study NCT01342601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)
Description: Comparison of ANS01 and AAT01 with placebo
Study NCT01342601 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo products
Description: Nasal Spray and Eye drops without Ectoin
Study NCT03590210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w
Study NCT03590210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Cycle 2 to 16 240 mg IV over 30 minutes, q3w
Study NCT02398864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS with TBNA
Description: endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
Study NCT02692443 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Brain MRI without Contrast
Study NCT02692443 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental Testing
Description: Validated battery of neurodevelopmental and psychological tests.
Study NCT03575377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disposal Aid
Description: Deterra® drug deactivation system
Study NCT02449850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food intervention
Description: Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
Study NCT02449850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin care
Description: Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
Study NCT05256186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basketball Pre-injury Attack program
Description: The intervention had a total duration of 24 weeks, with 3 sessions per week (before starting training) with a total duration of 12 to 15 minutes per session. Each session consisted of 8 exercises with a load of 2 to 3 series between 6 and 12 repetitions; and with a rest at the end of each series of \<60 seconds.
Study NCT04827498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment
Description: Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire
Study NCT01470092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone
Description: Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
Study NCT00910676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprosone
Description: * Start of treatment: as soon as the EGF-R inhibitors treatment begins~* Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~* Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~* Period of treatment: 8 weeks
Study NCT02557763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford unicompartmental knee arthroplasty
Description: The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
Study NCT00934024 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: varenicline
Description: Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
Study NCT00764465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID, 100 mg QD
Study NCT04146259 — intervention group
Intervention type: DRUG
Intervention: calcium carbonate and alphacalcidol
Description: treatment for hypocalcemia
Study NCT02452892 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LFMS
Description: Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.